CoChat

The CRTH 2 antagonist OC 000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo‐controlled, double‐blind trial

Horak, F., Zieglmayer, P., Zieglmayer, R., Lemell, P., Collins, L. P., Hunter, M. G., Steiner, J., Lewis, T., Payton, M. A., Perkins, C. M., Pettipher, R. · 2012 · Allergy
Cited by 85

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Background: CRTH 2 mediates activation of Th2 cells, eosinophils and basophils in response to prostaglandin D 2. The CRTH 2 antagonist OC 000459 has previously been demonstrated to reduce airway inflammation and improve lung function in moderate persistent asthma. The objective of the present study was to determine the involvement of CRTH 2 in promoting nasal and ocular symptoms in allergic subjects exposed to grass pollen. Methods: A single centre, randomised, double‐blind, placebo‐controlled, two‐way crossover study was conducted in 35 male subjects allergic to grass pollen comparing OC 000459 200 mg bid with placebo for 8 days. Subjects were exposed to grass pollen (≥1400 grains/m 3) for 6 h on the 2nd and 8th days of treatment and assessed for nasal symptoms, ocular symptoms, other symptoms, nasal secretion weight and rhinomanometry over the 6‐h period. After a washout period of 3 weeks, subjects were switched to the alternative treatment for a further 8 days. The trial was registered on the clinical trials.gov database (Identifier NCT 01448902). Results: During the first treatment period, treatment with OC 000459 significantly reduced both nasal and ocular symptoms in allergic subjects compared with placebo after challenge with grass pollen. A significant effect was observed on the 2nd day of dosing which was increased on the 8th day of dosing. The therapeutic effects of OC 000459 persisted into the second treatment period despite a 3‐week washout phase. The safety profile of OC 000459 was similar to that of placebo. Conclusion: Treatment with OC 000459 was well tolerated and led to a significant and persistent reduction in the symptoms of rhinoconjunctivitis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/all.12042

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 85

Metadata

Authors
Horak, F., Zieglmayer, P., Zieglmayer, R., Lemell, P., Collins, L. P., Hunter, M. G., Steiner, J., Lewis, T., Payton, M. A., Perkins, C. M., & Pettipher, R.
Venue
Allergy
Publisher
Wiley
Published
2012-10
Volume
67
Issue
12
Pages
1572-1579
ISSN
  • 0105-4538 (ISSN-L)
  • 1398-9995
OpenAlex
W2064998500
Cited by
85
References
1
FWCI
6.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The CRTH 2 antagonist OC 000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo‐controlled, double‐blind trial. https://app.cochat.ai/papers/10.1111/all.12042
The paper
Horak, F., Zieglmayer, P., Zieglmayer, R., Lemell, P., Collins, L. P., Hunter, M. G., Steiner, J., Lewis, T., Payton, M. A., Perkins, C. M., & Pettipher, R. (2012). The CRTH 2 antagonist OC 000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo‐controlled, double‐blind trial. Allergy. https://doi.org/10.1111/all.12042

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.